Deal Ends Today·Save 35% annual plan
CNS Stimulant, Schedule IIReviewed for 2026 plan year

Does Blue Cross Blue Shield of Texas Cover Vyvanse?

The verdict

Covered on most plans

Blue Cross Blue Shield of Texas covers Vyvanse through its HCSC/Prime Therapeutics formulary — generic lisdexamfetamine is preferred, brand Vyvanse is non-preferred as generic supply stabilizes. A Schedule II 70 mg/day quantity limit applies, and an ADHD diagnosis must be documented. Verify the exact tier and quantity limit on your BCBS TX plan formulary, as Texas Medicaid STAR plans and commercial plans may differ.

MedicareCovered
CommercialCovered
See the difference

Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Blue Cross Blue Shield of Texas using your member ID.

Reviewed for 2026
Checked against the active plan year
Sourced from formularies
Blue Cross Blue Shield of Texas drug lists + CMS guidance
Updated as rules change
Coverage and prior-auth criteria shift often
Verify before you decide
Informational only — not insurance advice
Plan types

Medicare vs. commercial coverage

Whether Blue Cross Blue Shield of Texas covers Vyvanse depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.

Medicare

Part D & Advantage plans

Covered

Medicare Part D (BCBS TX Part D): generic lisdexamfetamine is covered and generally preferred; brand Vyvanse may require prior authorization as generic supply improves. A Schedule II quantity limit of 70 mg/day applies. Verify the current tier on the BCBS TX Part D drug list, as formulary positions are updated annually.

Commercial / Employer

Group & marketplace plans

Covered

Commercial/Employer: generic lisdexamfetamine is preferred at a low tier via Prime Therapeutics (the HCSC family PBM); brand Vyvanse is non-preferred. A 70 mg/day quantity limit and ADHD-diagnosis requirement apply. ACA/Individual (marketplace) plans follow the same generic-preferred logic with QL. Texas Medicaid STAR (where BCBS TX participates): generic covered per the Texas Medicaid PDL with PA and QL; brand non-preferred. During 2024, some plans temporarily added brand Vyvanse back due to the generic shortage; those add-backs are now being reversed as supply improves — verify current formulary status. Shortage-documented prior authorization or pharmacist override can support brand dispensing when generic is unavailable.

Prior authorization

The 5 boxes you must tick to get approved

Commercial plans that will consider Vyvanse require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.

Requirements you meet0 / 5

Meet all 5 and you have a documented case for approval. Missing any one is the most common reason requests are denied.

What you'll pay

Your cost, three ways

What Vyvanse actually costs you swings enormously depending on how it's covered. Here's the realistic range.

No coverage

Paying cash

Brand Vyvanse: approx. $400–$558/month (Takeda list price, estimate). Generic lisdexamfetamine: approx. $200–$360/month cash, as low as approx. $60–$70 with a coupon.

List price with no coverage — before any manufacturer savings card.

PA approved

With coverage

Generic lisdexamfetamine at preferred tier: lowest cost-share tier (plan-specific copay or coinsurance — verify on BCBS TX formulary). Brand Vyvanse at non-preferred tier: higher cost-share; verify on plan formulary. Texas Medicaid STAR: nominal cost-share (typically $0–$4).

Typical monthly copay once prior authorization is approved.

All cost figures are estimates; actual cost-share depends on your specific BCBS TX plan tier, deductible phase, and benefit design. Verify current copays on the BCBS TX formulary or by calling member services. Texas Medicaid STAR cost-shares are nominal but verify through Texas Medicaid.

Do it yourself

Check YOUR exact coverage in 3 steps

General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.

  1. 1

    Search the BCBS TX online formulary

    Go to bcbstx.com and use the drug lookup tool with your specific plan. Search for both 'lisdexamfetamine' (generic) and 'Vyvanse' (brand) to see current tier, quantity limits, and prior auth requirements.

  2. 2

    Call BCBS TX member services

    Call the number on the back of your insurance card and ask specifically: (1) Is generic lisdexamfetamine covered on my plan, and at what tier? (2) Is brand Vyvanse covered, or is it non-preferred? (3) What is the quantity limit and is prior authorization required? Mention the DEA drug shortage if relevant.

  3. 3

    Work with your prescriber on prior authorization

    If your plan requires PA, your prescriber must submit documentation of your ADHD (or binge-eating disorder) diagnosis and the prescribed dose. For brand Vyvanse, document generic unavailability at local pharmacies if applicable. Texas Medicaid STAR PAs go through the plan's PA portal — confirm the process with your prescriber.

If it's denied

Options if Blue Cross Blue Shield of Texas won't cover Vyvanse

A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.

Generic lisdexamfetamine

The preferred, lowest-cost formulary option. FDA-approved August 2023; same active ingredient as brand Vyvanse at substantially lower cash price (approx. $200–$360/month vs. $400–$558/month for brand). Verify availability at your pharmacy — intermittent shortage continues.

Generic amphetamine/dextroamphetamine (Adderall generic)

Covered on BCBS TX formulary at a low tier (generic preferred). Different chemical entity from lisdexamfetamine; prescriber must evaluate whether it is clinically appropriate. Cash approx. $17–$55/30 days.

Amphetamine extended-release generics (e.g., mixed amphetamine salts XR)

Various generic extended-release amphetamine formulations are typically formulary-preferred at low cost-share. Ask your prescriber and verify on the BCBS TX formulary.

These options are listed for information only — your own clinician decides what is appropriate for you.

Frequently Asked Questions

BCBS of Texas formularies — using Prime Therapeutics as the HCSC family PBM — now prefer generic lisdexamfetamine over brand Vyvanse. Brand Vyvanse is non-preferred; many HCSC-family plans temporarily added it back during the 2024 generic shortage and are now reversing those add-backs. Brand coverage may still be available with a formulary exception or shortage-documented PA. Verify on your specific BCBS TX plan formulary, as commercial and Medicaid tiers differ.

The Schedule II quantity limit for lisdexamfetamine (Vyvanse/generic) is 70 mg per day on BCBS TX-aligned plans, consistent with the FEP standard criteria (CVS Caremark Policy 5.60.024, eff. April 1, 2026). No refills without a new Schedule II prescription. Texas Medicaid STAR plans may apply their own PDL-based quantity limits — verify on the Texas Medicaid formulary.

Prior authorization is typically required on BCBS TX plans for brand Vyvanse (non-preferred) and may be required for generic lisdexamfetamine depending on the specific plan. PA criteria include documented ADHD or adult binge-eating disorder diagnosis, quantity within the 70 mg/day limit, and generic substitution where available. Texas Medicaid STAR plans may also require PA for stimulants with a one-stimulant-at-a-time rule. Verify current PA requirements with your prescriber.

Where BCBS Texas participates in the Texas Medicaid STAR program, generic lisdexamfetamine is generally covered per the Texas Medicaid PDL with PA and quantity limits. Brand Vyvanse is non-preferred. Texas Medicaid STAR stimulant PA criteria typically allow only one stimulant at a time. Verify Vyvanse coverage on the Texas Medicaid PDL or with your managed care plan, as Medicaid formularies are state-regulated.

If generic lisdexamfetamine is unavailable, document the shortage at your pharmacy and ask your prescriber to file a prior authorization for brand Vyvanse citing the shortage. Prime Therapeutics and most PBMs allow pharmacist overrides or shortage-documented PAs for brand dispensing when the generic cannot be filled. The DEA raised the 2026 lisdexamfetamine production quota to over 51 million grams, but supply conversion takes time.

This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Blue Cross Blue Shield of Texas before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation.